V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003314 | 320001999 | 1.94 | 85 | Palliative (P) | 2014-04-09 | 2014-05-04 | TEMOZOLOMIDE | N | N | 320019917 | CETUXIMAB + RT |
| 320003316 | 320002001 | 1.59 | 85.6 | Adjuvant (A) | 2013-07-12 | 2013-07-12 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | 320019920 | ENZALUTAMIDE |
| 320003317 | 320002002 | null | 77 | Curative (C) | 2015-06-07 | 2015-06-08 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | Y | 320019929 | CETUXIMAB + CISPLATIN + FU |
| 320003318 | 320002003 | 1.72 | 82 | Curative (C) | 2013-03-01 | 2013-03-02 | CARBOPLATIN + RT | N | Y | 320019939 | POUT TRIAL |
| 320003319 | 320002004 | 1.73 | 94.15 | Palliative (P) | null | 2014-06-18 | ECarboF | null | null | 320019949 | CISPLATIN + GEMCITABINE |
| 320003320 | 320002004 | 1.78 | 67.5 | Curative (C) | 2014-02-15 | 2014-02-15 | Carboplatin + Etoposide IV 3 day | 2 | N | 320019949 | CAPECITABINE |
| 320003321 | 320002004 | 1.78 | 95.4 | Curative (C) | 2013-08-17 | 2013-09-07 | CETUXIMAB + RT | N | N | 320019949 | CETUXIMAB + RT |
| 320003323 | 320002006 | 1.62 | 95.3 | Curative (C) | 2017-04-25 | 2017-04-25 | Trial Unspecified | 02 | N | 320019988 | VISMODEGIB |
| 320003324 | 320002007 | 1.71 | 91 | null | 2015-09-06 | 2015-09-06 | BCG Intravesical | 01 | null | 320020001 | CISPLATIN + VINORELBINE |
| 320003334 | 320002010 | 1.73 | 127 | Adjuvant (A) | null | 2015-11-17 | STS Rhabdomyosarcoma RMS 2005 IVA | Y | N | 320020114 | EC |
| 320003335 | 320002011 | 1.2 | 151 | Palliative (P) | 2017-03-11 | 2017-03-13 | Capecitabine | N | N | 320020119 | PEMBROLIZUMAB |
| 320003336 | 320002012 | 1.66 | 86.7 | Disease modification (D) | null | 2013-12-09 | FLUOROURACIL + IRINOTECAN | 02 | null | 320020123 | IRINOTECAN + MDG + PANITUMUMAB |
| 320003337 | 320002013 | 1.63 | 64.4 | Adjuvant (A) | 2015-05-27 | 2015-06-15 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320020124 | TRIAL |
| 320003339 | 320004990 | 1.56 | 54.6 | Neo-adjuvant (N) | 2013-01-01 | 2013-02-12 | Cisplatin + Doxorubicin | 02 | N | 320020160 | BEVACIZUMAB |
| 320003340 | 320004990 | 1.5 | 108.8 | Neo-adjuvant (N) | 2014-09-20 | 2014-09-28 | DACARBAZINE + VINDESINE | N | Y | 320020160 | OXALIPLATIN + MDG |
| 320003341 | 320004990 | 1.67 | 108 | Neo-adjuvant (N) | 2017-09-30 | 2017-10-13 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320020160 | NOT MATCHED |
| 320003342 | 320007223 | 1.73 | 71.5 | Adjuvant (A) | 2013-08-20 | 2013-08-20 | CHOP R - 21 days | 02 | N | 320020195 | CISPLATIN + GEMCITABINE |
| 320003343 | 320007223 | 1.85 | 70 | Adjuvant (A) | 2014-10-02 | 2014-10-26 | ABVD | N | N | 320020195 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003344 | 320002015 | 1.82 | 76.1 | Neo-adjuvant (N) | 2014-07-23 | 2014-08-03 | BCG Intravesical | null | null | 320020214 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 320003345 | 320002015 | 1.74 | 50 | Palliative (P) | 2017-01-26 | 2017-01-30 | BORTEZOMIB + THALIDOMIDE | N | N | 320020214 | OCTREOTIDE |
| 320003346 | 320002016 | 1.53 | 60.6 | Curative (C) | 2014-11-09 | 2014-12-12 | BLEOMYCIN + CISPLATIN + MITOMYCIN | N | N | 320020274 | SORAFENIB |
| 320003349 | 320002017 | 1.78 | 79.9 | Disease modification (D) | 2016-04-03 | 2016-04-11 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 1 | N | 320020281 | BEVACIZUMAB |
| 320003350 | 320002018 | 1.68 | 73 | Palliative (P) | 2018-05-23 | 2018-05-23 | PEMBROLIZUMAB | 2 | N | 320020283 | MPV |
| 320003351 | 320002019 | 1.74 | 86.3 | null | 2015-03-16 | 2015-03-19 | Cyclophosphamide + Dex + Rituximab | Y | null | 320020286 | CTD |
| 320003352 | 320002020 | 1.83 | 66.7 | Palliative (P) | 2017-08-11 | 2017-08-17 | Cisplatin + Paclitaxel | 02 | N | 320020317 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320003353 | 320002021 | 1.75 | 0 | Curative (C) | 2018-01-16 | 2018-01-16 | BLEOMYCIN | 2 | N | 320020319 | ECX |
| 320003354 | 320002022 | 1.7 | 95 | Neo-adjuvant (N) | 2013-09-19 | 2013-09-30 | Vinflunine | N | N | 320020326 | CARBOPLATIN + RT |
| 320003355 | 320004993 | 1.61 | 82 | Adjuvant (A) | 2014-10-19 | 2014-11-03 | Ipilimumab | N | Y | 320020339 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003356 | 320004993 | 1.59 | 77.5 | Neo-adjuvant (N) | 2017-07-26 | 2017-07-27 | TEMOZOLOMIDE | N | N | 320020339 | FLUOROURACIL + MITOMYCIN + RT |
| 320003357 | 320002023 | 1.7 | 71 | Adjuvant (A) | 2015-12-01 | 2015-12-09 | CHOP R - 21 days | 2 | null | 320020348 | CETUXIMAB |
| 320003358 | 320002024 | null | 50.5 | Palliative (P) | 2017-06-28 | 2017-07-12 | ICON8B TRIAL | N | N | 320020359 | BCG |
| 320003359 | 320002025 | 1.76 | 84.3 | Curative (C) | 2017-08-03 | 2017-08-29 | POUT TRIAL | N | Y | 320020374 | EPIRUBICIN |
| 320003360 | 320002026 | null | 60.8 | Adjuvant (A) | 2016-05-19 | 2016-05-23 | IPILIMUMAB + NIVOLUMAB | N | N | 320020395 | CISPLATIN + GEMCITABINE |
| 320003361 | 320002027 | null | null | Palliative (P) | 2015-06-23 | 2015-07-19 | FEC + DOCETAXEL | null | N | 320020409 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320003362 | 320004994 | 1.6 | 84.8 | Palliative (P) | 2017-05-17 | 2017-05-19 | CARBOPLATIN + RT | 2 | N | 320020416 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320003363 | 320002028 | 1.75 | null | Adjuvant (A) | 2014-01-03 | 2014-01-24 | Cetuximab + Radiotherapy Load | N | Y | 320020419 | CISPLATIN + GEMCITABINE |
| 320003364 | 320002029 | 1.72 | 121 | Palliative (P) | null | 2014-09-05 | CETUXIMAB | N | N | 320020423 | NIVOLUMAB |
| 320003365 | 320002030 | null | 67.2 | Curative (C) | 2015-11-07 | 2015-05-17 | Bevacizumab + CARBOPLATIN + PACLITAXEL | null | N | 320020431 | CISPLATIN + DOCETAXEL |
| 320003367 | 320002032 | 1.73 | 79.6 | Palliative (P) | 2016-09-10 | 2016-09-14 | CETUXIMAB | N | N | 320020438 | CETUXIMAB + RT |
| 320003368 | 320002033 | 1.58 | 59.2 | Adjuvant (A) | 2017-02-11 | 2017-02-17 | Bevacizumab+Carbo+Pacliaxel | N | N | 320020445 | CARBOPLATIN + PEMETREXED |
| 320003370 | 320002035 | 1.56 | 55 | Palliative (P) | 2013-12-24 | 2014-01-01 | POUT TRIAL | N | N | 320020464 | FLUOROURACIL + MITOMYCIN + RT |
| 320003371 | 320002036 | 1.6 | 68 | Adjuvant (A) | 2016-05-08 | 2016-06-03 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320020504 | EVEROLIMUS |
| 320003372 | 320002037 | 1.79 | 71.2 | Adjuvant (A) | 2016-06-13 | 2016-06-20 | Everolimus 10mg | 1 | null | 320020508 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003373 | 320002038 | null | 67.2 | Disease modification (D) | 2015-11-12 | 2015-05-22 | CAPECITABINE + OXALIPLATIN | null | N | 320020513 | BEVACIZUMAB |
| 320003374 | 320002038 | 1.66 | 73.7 | Curative (C) | 2015-06-26 | 2015-06-30 | CARBOPLATIN + RT | N | Y | 320020513 | IMATINIB |
| 320003375 | 320006337 | 1.58 | 68 | Adjuvant (A) | 2015-11-16 | 2015-11-30 | Bevacizumab+Carbo+Gemcitabine | 02 | N | 320020540 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320003376 | 320006337 | 1.68 | null | Neo-adjuvant (N) | null | 2018-01-06 | Paclitaxel (2 or 3 weekly) | null | null | 320020540 | BEVACIZUMAB |
| 320003377 | 320002039 | 1.45 | 66.9 | Curative (C) | null | 2013-07-21 | CNS GCT II Non Germin - Std PEI | N | N | 320020550 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003378 | 320002039 | 1.71 | 62.8 | Palliative (P) | 2014-09-09 | 2014-09-15 | BCG Intravesical | Y | N | 320020550 | EPIRUBICIN |
| 320003380 | 320002041 | 1.91 | 70.5 | Adjuvant (A) | null | 2013-12-19 | Everolimus 5mg | N | N | 320020577 | CETUXIMAB + RT |